Drug Approval | February 19, 2022
EC approves Tepmetko to treat non-small cell lung cancer
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
